Anti-Cancer

Everolimus (AFINITOR) Tablet

$1,392.00

This description provides an overview of Everolimus tablets (AFINITOR) in 5 mg and 10 mg strengths, including indications, dosage, administration, contraindications, warnings, precautions, adverse reactions, drug interactions, and storage information. Patients should consult their healthcare provider for personalized information and guidance regarding the use of Everolimus.

Strength	Choose an option5mg10mg
	Clear

Quantity

Everolimus (AFINITOR) Tablet quantity

Add to cart

Sku:

N/A

Tag:

Everolimus AFINITOR

Description

Everolimus is a medication that belongs to a class of drugs known as mammalian target of rapamycin (mTOR) inhibitors. It is available in tablet form for oral administration.

Indications: Everolimus is indicated for the treatment of various types of cancers and certain non-cancerous conditions. Specifically, it is used for the following indications:

1. Advanced renal cell carcinoma (RCC): Everolimus is indicated for the treatment of patients with advanced RCC after failure of treatment with sunitinib or sorafenib.
2. Advanced hormone receptor-positive, HER2-negative breast cancer: Everolimus, in combination with exemestane, is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer.
3. Pancreatic neuroendocrine tumors (PNET): Everolimus is indicated for the treatment of adults with progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal or lung origin that are unresectable, locally advanced, or metastatic.
4. Advanced non-functional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin: Everolimus is indicated for the treatment of adults with progressive, well-differentiated, non-functional NET of GI or lung origin that are unresectable, locally advanced, or metastatic.
5. Renal angiomyolipoma associated with tuberous sclerosis complex (TSC): Everolimus is indicated for the treatment of adults with renal angiomyolipoma associated with TSC who do not require immediate surgery.
6. Subependymal giant cell astrocytoma (SEGA) associated with TSC: Everolimus is indicated for the treatment of adults and pediatric patients aged 1 year and older with SEGA associated with TSC who require therapeutic intervention but are not candidates for curative surgical resection.
7. Renal angiomyolipoma and SEGA associated with TSC: Everolimus is indicated for the treatment of pediatric and adult patients with renal angiomyolipoma and SEGA associated with TSC who require therapeutic intervention but are not candidates for surgical resection.

Mechanism of Action: Everolimus inhibits the mammalian target of rapamycin (mTOR), which is a protein kinase that regulates cell growth, proliferation, and survival. By inhibiting mTOR, Everolimus interferes with various cellular processes involved in the progression of cancer and other diseases.

Administration: Everolimus tablets should be taken orally once daily, preferably at the same time each day, with or without food. The tablets should be swallowed whole with a glass of water and should not be crushed, chewed, or split.

Dosage and Administration:

• The recommended dosage of Everolimus varies depending on the indication for which it is being used.
• The dosage may need to be adjusted based on the patient’s individual response to treatment and any adverse reactions experienced.
• It is important for patients to follow the dosage instructions provided by their healthcare provider.
• Patients should not adjust their dosage or stop taking Everolimus without consulting their healthcare provider.

Contraindications: Everolimus is contraindicated in patients with hypersensitivity to Everolimus or any of the excipients in the formulation. It is also contraindicated in patients with severe hepatic impairment.

Warnings and Precautions: Before initiating treatment with Everolimus, healthcare providers should consider the following:

• Risk of infections: Everolimus can increase the risk of developing infections, including opportunistic infections. Patients should be monitored for signs and symptoms of infection during treatment.
• Risk of non-infectious pneumonitis: Everolimus can cause non-infectious pneumonitis, which can be fatal. Patients should be monitored for respiratory symptoms, and treatment should be interrupted or discontinued if pneumonitis is suspected.
• Adverse Reactions: The most common adverse reactions associated with Everolimus treatment include stomatitis, infections, rash, fatigue, diarrhea, edema, nausea, fever, cough, headache, decreased appetite, vomiting, and abdominal pain.

Drug Interactions: Everolimus may interact with other medications, including strong inhibitors or inducers of cytochrome P450 3A4 (CYP3A4) and medications that prolong the QT interval. Patients should inform their healthcare provider about all medications they are taking, including prescription, over-the-counter, and herbal supplements, before starting treatment with Everolimus.

Storage: Everolimus tablets should be stored at controlled room temperature (25°C) in the original container, protected from light and moisture. Keep out of reach of children.

Manufacturer: AFINITOR tablets are manufactured by Novartis Pharmaceuticals Corporation.

This description provides an overview of Everolimus tablets (AFINITOR) in 5 mg and 10 mg strengths, including indications, dosage, administration, contraindications, warnings, precautions, adverse reactions, drug interactions, and storage information. Patients should consult their healthcare provider for personalized information and guidance regarding the use of Everolimus.

Additional information